% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Northcott:143453,
      author       = {P. A. Northcott and G. W. Robinson and C. P. Kratz and D.
                      J. Mabbott and S. L. Pomeroy and S. C. Clifford and S.
                      Rutkowski and D. W. Ellison and D. Malkin and M. D. Taylor
                      and A. Gajjar and S. Pfister$^*$},
      title        = {{M}edulloblastoma.},
      journal      = {Nature reviews / Disease Primers Disease Primers [...]},
      volume       = {5},
      number       = {1},
      issn         = {2056-676X},
      address      = {Basingstoke},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2019-01041},
      pages        = {11},
      year         = {2019},
      abstract     = {Medulloblastoma (MB) comprises a biologically heterogeneous
                      group of embryonal tumours of the cerebellum. Four subgroups
                      of MB have been described (WNT, sonic hedgehog (SHH), Group
                      3 and Group 4), each of which is associated with different
                      genetic alterations, age at onset and prognosis. These
                      subgroups have broadly been incorporated into the WHO
                      classification of central nervous system tumours but still
                      need to be accounted for to appropriately tailor disease
                      risk to therapy intensity and to target therapy to disease
                      biology. In this Primer, the epidemiology (including MB
                      predisposition), molecular pathogenesis and integrative
                      diagnosis taking histomorphology, molecular genetics and
                      imaging into account are reviewed. In addition, management
                      strategies, which encompass surgical resection of the
                      tumour, cranio-spinal irradiation and chemotherapy, are
                      discussed, together with the possibility of focusing more on
                      disease biology and robust molecularly driven patient
                      stratification in future clinical trials.},
      subtyp        = {Review Article},
      cin          = {B062 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30765705},
      doi          = {10.1038/s41572-019-0063-6},
      url          = {https://inrepo02.dkfz.de/record/143453},
}